Ipsen is committed to providing simple lay/plain language results summaries of all our interventional clinical trials that started from January 2022 or started before January 2022 and with an end date after January 2023. The summaries aim to make clinical study information accessible to everyone. They are typically published within a year following the end of the trial or shortly after the marketing authorization has been granted. Local language translations may be available upon request.
Contact clinical.trials@ipsen.com for more information.
On this page you can find summaries of clinical trials that Ipsen has sponsored and clinical trials that were acquired by Ipsen. You can use the search bar to find summaries by keyword and the drop-down list to find summaries by condition(s).
The summaries provided here serve informational purposes and are not intended for promotional use. They do not constitute any form of endorsement, recommendation, or solicitation. Instead, they fulfill regulatory requirements and reflect our commitment to transparency regarding clinical trials.
Contact
-
Product & medical information
-
-
Patients Centricity
-
Filter
Condition
Period
Filter by
recent search
Showing: 1 – 05 of 3 Conditions
–
05 May 2023
05 May 2023
LinkedIn
Facebook
Fibrodysplasia ossificans progressiva burden of disease study
A study to evaluate the impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members.
–
05 May 2023
05 May 2023
Phase III ENGAGE study
A study to evaluate the effects of Dysport® in patients living with spastic hemiparesis in combination with a prescribed personal rehabilitation program.
–
05 May 2023
05 May 2023
LinkedIn
Phase III CLARINET study
A study on the effectiveness of somatuline autogel (lanreotide autogel) as a treatment for patients with non-functioning neuroendocrine tumours of the pancreas, intestines, or unknown origin.